Detail
| LncRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 Sequence |
| Ensembl | ENSG00000177640 |
| RefSeq | NR_026939 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | glioma |
| ICD-0-3 | M9380/3 |
| Methods | qPCR, Western blot, Luciferase report assay etc. |
| Sample | glioma tissues, cell lines (U251 and U87) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 expression was significantly downregulated in glioma tissues and cell lines (U87 and U251) compared to adjacent normal brain tissues or normal human astrocytes. CASC2 may potentially serve as a valuable diagnostic and prognostic biomarker and a therapeutic target for glioma patients.CASC2 could be considered as an independent risk factor for poor prognosis. CASC2 overexpression remarkably suppressed glioma cell proliferation, migration, and invasion through suppressing Wnt/B-catenin signaling pathway. |
| Pubmed ID | 28744130 |
| Year | 2017 |
| Title | Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/B-catenin signaling pathway. |
| External Links |
| Links for CASC2 | GenBank HGNC lncrnadb Noncode |
| Links for glioma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.